Literature DB >> 10693883

Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom.

R A Watts1, S E Lane, G Bentham, D G Scott.   

Abstract

OBJECTIVE: To describe the epidemiology of the primary systemic vasculitides (PSV; Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, polyarteritis nodosa) in a well-defined population over a 10-year period.
METHODS: An inception cohort of patients from the Norwich Health Authority (NHA) who were >15 years of age and had PSV first diagnosed between January 1, 1988 and December 31, 1997 was collected. Incidence rates were adjusted for age and sex to the 1992 population. The prevalence of PSV in this cohort was estimated on December 31, 1997. Patients were classified according to the American College of Rheumatology 1990 vasculitis criteria and the Chapel Hill Consensus definitions.
RESULTS: Eighty-two NHA residents fulfilled the inclusion criteria. There were 47 men and 35 women, with a mean age of 62.9 years (median 65.0 years). The overall annual incidence of PSV among NHA residents was 19.8/million (95% confidence interval [95% CI] 15.8-24.6). The point prevalence on December 31, 1997 was 144.5/million (95% CI 110.4-185.3). PSV was more common in males (23.5/million; 95% CI 17.3-31.3) than females (16.4/million; 95% CI 11.4-22.8). The age- and sex-specific incidence showed a clear increase with age, with an overall peak in the 65-74 year age group (60.1/million).
CONCLUSION: In our study population, the annual incidence of PSV is slowly increasing with time and the incidence is greatest in the elderly.

Entities:  

Mesh:

Year:  2000        PMID: 10693883     DOI: 10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  106 in total

Review 1.  Perspective on future therapy of vasculitis.

Authors:  D T Boumpas; H D Kritikos; N G Daskalakis
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

Review 2.  Polyarteritis nodosa and microscopic polyangiitis: etiologic and diagnostic considerations.

Authors:  Laura B Hughes; S Louis Bridges
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

3.  [Initial skin manifestations of Wegener's disease].

Authors:  M Klammer; G R Hetzel; G Fürst; H E Gabbert; M Megahed; T Ruzicka; U R Hengge
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

4.  An unusual complication of polyarteritis nodosa with massive retroperitoneal hemorrhage: a case report.

Authors:  Prashanth Peddi; Jagadeesh K Kalavakunta; Madhavi Annakula; John R Armstrong
Journal:  Int Arch Med       Date:  2010-11-11

Review 5.  The lung in systemic vasculitis: radiological patterns and differential diagnosis.

Authors:  Beatrice Feragalli; Cesare Mantini; Marco Sperandeo; Michele Galluzzo; Giovanni Belcaro; Armando Tartaro; Antonio R Cotroneo
Journal:  Br J Radiol       Date:  2016-02-15       Impact factor: 3.039

Review 6.  Granulomatosis with polyangiitis in childhood.

Authors:  Marinka Twilt; Susanne Benseler; David Cabral
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

Review 7.  Polyarteritis nodosa presenting as pancytopenia: case report and review of the literature.

Authors:  Leslie R Harrold; Nancy Y N Liu
Journal:  Rheumatol Int       Date:  2008-03-27       Impact factor: 2.631

Review 8.  Benefit-risk assessment of antileukotrienes in the management of asthma.

Authors:  Luis García-Marcos; Antje Schuster; Eduardo G Pérez-Yarza
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  A case of polyarteritis nodosa presenting initially as peripheral vascular disease.

Authors:  Serge De Golovine; Sameer Parikh; Lee Lu
Journal:  J Gen Intern Med       Date:  2008-06-17       Impact factor: 5.128

10.  Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years.

Authors:  C Turesson; W M O'Fallon; C S Crowson; S E Gabriel; E L Matteson
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.